PRODUCT TYPES – Page 5

API photostability failure during tech transfer to a new site: how to write a defensible deviation narrative for inspections

The initial signs of a photostability failure during a tech transfer may manifest in various ways. Recognizing these symptoms early is crucial for containment and mitigation. Common signals include:Click to…

API nitrosamine risk exceedance after equipment maintenance intervention: GMP investigation checklist and batch disposition evidence pack

Identification of symptoms indicative of nitrosamine risk exceedance is the first step in an effective investigation. Common signals include:Click to read the full article.

API assay drift during CPV trending review: regulatory impact assessment and change control remediation plan

Identifying early signals of assay drift is critical for maintaining compliance with GMP standards. Symptoms may present in several forms:Click to read the full article.

API nitrosamine risk exceedance after cleaning validation requalification: GMP investigation checklist and batch disposition evidence pack

In any manufacturing or laboratory environment, timely identification of symptoms related to API nitrosamine risk exceedance is crucial. Below are critical signals that may indicate an excessive level of nitrosamine…

API nitrosamine risk exceedance after milling / micronization change: risk-based approach to prevent repeat OOS across future API batches

Identifying early signs of nitrosamine risk exceedance is crucial for timely intervention. Key symptoms may include:Click to read the full article.

API batch-to-batch variability trend (OOT) during process validation campaign: root cause analysis (process vs lab) with CAPA effectiveness checks

In the early stages of a deviation investigation, identifying symptoms or signals is crucial for recognizing potential variability trends of APIs. Signs may include:Click to read the full article.

API heavy metals / elemental impurities OOS after re-crystallization parameter adjustment: supplier qualification gaps and incoming testing upgrades to close the loop

Recognizing the symptoms associated with OOS results is crucial for an effective investigation. Common signals associated with heavy metals or elemental impurities OOS can include:Click to read the full article.

API water content (KF) OOS during FDA inspection readiness: how to justify reprocessing vs rejection to FDA/EMA inspectors

Detecting OOS results begins with recognizing the symptoms and signals that may indicate a problem with the API water content. Laboratories and manufacturing floors must be vigilant to prevent potential…

API genotoxic impurity (GTI) breach after equipment maintenance intervention: how to justify reprocessing vs rejection to FDA/EMA inspectors

When a genotoxic impurity breach occurs, the first signals may come from various areas of the manufacturing floor or quality control (QC) lab. These symptoms can manifest as:Click to read…

API endotoxin risk in sterile API after drying cycle optimization: control strategy updates for CPPs/CMAs and continued process verification

Identifying symptoms and signals is crucial for timely intervention during abnormalities in the drying processes of sterile APIs. Symptoms that may indicate elevated endotoxin levels include:Click to read the full…

Aseptic manipulation deviation during FDA inspection readiness: regulatory risk assessment and CAPA

The initial step in identifying an aseptic manipulation deviation is recognizing symptoms or signals which may manifest in the production environment or laboratory. These signals may not always be direct;…

API bulk density variability after solvent change in last step: how to justify reprocessing vs rejection to FDA/EMA inspectors

The detection of bulk density variability typically surfaces through multiple channels, from routine quality checks to customer complaints. Here are key symptoms to monitor:Click to read the full article.